ReOxy Therapy in the Rehabilitation of Chronic Low Back Pain Patients With Comorbidity

Low Back Pain Clinical Trial

Official title:

The Respiratory Therapy Method Based on Short-term Intermittent Exposures Hypoxia and Hyperoxia (ReOxy Therapy) in the Rehabilitation of Chronic Low Back Pain Patients With Cardiac or Pulmonary Comorbidities: a Randomized Controlled Trial

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05053672
• Other study ID #: 4 11052021
• Status: Completed
• Phase: N/A
• Start date: June 1, 2021
• Est. completion date: April 20, 2022

Study information

• Verified date: March 2022
• Source: Moscow Scientific and Practical Center of Medical Rehabilitation, Restorative and Sports Medicine
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The aim of this study is to assess the effect of the respiratory therapy method based on short-term intermittent exposures to hypoxia and hyperoxia (ReOxy therapy) on the pain intensity, restoration of the lumbar range of motion, physical capacity, disability, mental and vegetative status in Chronic Low Back Pain patients with Multiple Chronic Conditions.

Description:

This is a randomized, single-blinded, placebo-controlled trial, with chronic non-specific low back pain with multiple chronic conditions. Comorbidity constitutes a serious challenge for rehabilitative medicine - significantly reduces the patients' quality of life and restoration of the working capacity.

The objective of the present study will be to evaluate the effectiveness of the combined non-medicinal rehabilitation programe which include a course of ReOxy- therapy and conventional therapy back pain treatment.

90 patients will be randomly allocated to three treatment groups: experimental ("hypoxic group" - ReOxy therapy + conventional therapy back pain treatment), placebo ("sham hypoxic group"- sham- ReOxy therapy + conventional therapy back pain treatment) and control (only conventional therapy back pain treatment).

The clinical outcomes will be obtained at the completion of treatment (2 weeks) and at 1 month after randomization. The statistical analysis will follow the intention-to-treat principles and the between-group differences will be calculated by using mixed linear models.

The outcomes of interest are pain intensity, lumbar range of motion function, general physical and mental status.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 90
• Est. completion date: April 20, 2022
• Est. primary completion date: April 15, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

• Patient with non-specific chronic low back pain for at least 3 months;

• A pain intensity of at least 5 points measured by 0 -10 points pain rating scale;

• Co-morbidity - IHD and/or CHF and/or COPD and/or chronic bronchitis)

• Willing and able to consent, complete all assessment and study procedures;

Exclusion Criteria:

• Specific types of back pain (metastatic cancer or bone cancer or secondary cancers, vertebral fractures, spinal infection, active inflammatory disease);

• Low back surgery within past 3 months;

• Serious cardiovascular, cerebrovascular, neuromuscular and other systemic diseases or other diseases affecting physical activity;

• Any significant systemic illness or medical condition that could affect safety or compliance with study;

• Major active or chronic unstable psychiatric illness (e.g. depression, bipolar disorder, obsessive compulsive disorder, schizophrenia) within the previous year;

• Tumour disease except being successfully treated and off treatment with >2 years. Tumour disease except being successfully treated and off treatment with >2 years.

• Use of other investigational agents or interventions one month prior to entry and for the duration of the trial;

Related Conditions & MeSH terms

• Back Pain
• Low Back Pain

Intervention

Device:
• ReOxy
ReOxy therapy is a protocol which employs passive (the patient is at rest), short (up to 10 min) mild normobaric hypoxic exposures alternated with similar duration intervals of breathing hyperoxia (up to 5 min). The gas mixtures are supplied to a patient via facial mask on continued measuring of oxygenation status of the patients, lasting about 45 min in total per treatment session. The hypoxic load will be individually adjusted, based on the results of a preliminary hypoxic test. The patient inhales air with low oxygen content (10-14%) at atmospheric pressure in a continuous mode through a mask withing 10-min. During the ReOxy - treatment session, the software automatically adjusts the gas mixture switching, based on changes in physiological parameters (blood oxygen saturation and heart rate) in response to hypoxic and hyperoxic impact (biofeedback control).
• Sham ReOxy
Placebo treatment with 'sham' ambient air breathing to simulate ReOxy-therapy sessions. Placebo-mode breathing set visually similar to standard breathing set but have a mask with open intake valve. The masks are chosen in a way to provide maximum degree of similarity to reduce the risk of unblinding on the patient-side.

Locations

Country	Name	City	State
Russian Federation	Moscow Scientific and Practical Center of Medical Rehabilitation, Restorative and Sports Medicine, Dept. No. 9	Moscow

Sponsors (1)

Lead Sponsor	Collaborator
Moscow Scientific and Practical Center of Medical Rehabilitation, Restorative and Sports Medicine

Country where clinical trial is conducted

Russian Federation, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	HR recovery after the 6-minute walk test	HR recovery measured by sphygmomanometer after the 6-minute walk test	Baseline and end of the 2-nd week
Other	SAD/DAD recovery after the 6-minute walk test	SAD/DAD recovery measured by sphygmomanometer after the 6-minute walk test	Baseline and end of the 2-nd week
Primary	Back pain intensity will be measured by the Visual Analog Scale	Visual analogue scale (VAS) is a simple and frequently used method for the assessment of variations in intensity of pain. The VAS consists of a 10cm horizontal line with the words "no pain" and "worst pain" at the line's end. VAS is a reliable and valid tool to reliable and valid tool to measure pain intensity measure pain intensity.	Baseline, end of the 2-nd week
Secondary	Back pain intensity	Back pain intensity will be measured by the Visual Analog Scale Visual analogue scale (VAS) is a simple and frequently used method for the assessment of variations in intensity of pain. The VAS consists of a 10cm horizontal line with the words "no pain" and "worst pain" at the line's end. VAS is a reliable and valid tool to reliable and valid tool to measure pain intensity measure pain intensity.	Baseline and 1-month post randomization
Secondary	Roland Disability Questionnaire (RDQ)	The Roland-Morris Questionnaire is a self-administered disability measure in which greater levels of disability are reflected by higher numbers on a 24-point scale	Baseline and 1-month post randomization
Secondary	Lumbar Range of Motion	Will be evaluated through the finger-to-floor test. Participant try to reach the floor with his fingertip by bending forward in the same time knees are kept extended. The distance between fingertips and floor are measured in centimetres by examiner.	Baseline, end of the 2-nd week
Secondary	Change of lower back flexibility	Will be evaluated through Schober test (positive/negative). The examiner places one finger 5cm below the mark pproximately at the level of L5 and another finger at about 10cm above this mark. The patient is then instructed to touch his toes. If the increase in distance between the two fingers on the patients spine is less than 5cm then this is indicative of a limitation of lumbar flexion.	Baseline, end of the 2-nd week
Secondary	6 min-walking test distance	Change in walking distance in meters during a 6-min period over a corridor of 30m length	Baseline, end of the 2-nd week
Secondary	Hospital Anxiety and Depression Scale, HADS	The Hospital Anxiety and Depression Scale (HADS) is a questionnaire, comprising fourteen questions. Each item on the questionnaire is scored from 0-3. The scale is devided into 2 parts: (1) anxiety (minimum score 0, maximum sore 21) and (2) depression (minimum score 0, maximum sore 21).; Scoring : 0-7- normal, 8-10-borderling abnormal, 11-21-abnormal	Baseline and 1-month post randomization
Secondary	Bergen Insomnia Scale (BIS)	The BIS comprises six items that assesses symptoms of insomnia based on the insomnia criteria found in the Diagnostic and Statistical Manual of Mental Disorders-IV-TR (American Psychiatric Association). Higher values indicate higher levels of insomnia severity.	Baseline and 1-month post randomization